Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease
The fundamental therapeutic mechanism of allogeneic hematopoietic stem cell transplantation (HCT) in hematologic malignancies is the graft-versus-tumor reactivity mediated by donor T cells. While severe acute graft-versus-host disease (aGVHD) is a clinical situation to be avoided, patients affected tend to show fewer
relapses [3]. Even so, aGVHD is the most relevant complication of allogeneic HCT and the mortality of steroid-refractory grade III and IV aGVHD is unacceptably high. The response to therapy after fi rstline treatment with glucocorticoids is still limited despite the advantage of recently introduced ruxolitinib.
Preview
Rights
Use and reproduction:
Please note that individual components of the publication may be subject to other licensing or copyright conditions.